Preclinical studies have demonstrated the feasibility of RNA‐based therapeutics in central nervous system disorders, particularly when coupled with advanced nanotechnology‐enabled delivery systems.[33] However, clinical translation of NEAT1‐targeted therapies faces several hurdles, including the lack of validated brain‐specific delivery systems, risk of off‐target effects in non‐neuronal tissues, and insufficient data on pharmacokinetics, biodistribution, and long‐term safety. Here, NEAT1 is linked to central nervous system disorder.